Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units ("Units") at a price of $0.08 per Unit, for gross proceeds of up to CND$800,000 (the "Offering"). Each Unit shall be comprised of one common share in the capital of the Company (each, a "Common... Read More

Voyageur Pharmaceuticals Ltd . (TSXV:VM) ( OTC :VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, on December 19, 2023, it issued 590,735 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company effective... Read More

Calgary, Canada - TheNewswire - December 21, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is excited to announce that its carbon capture and drug development partner, Rain Cage Carbon Inc. (“Rain Cage”), has successfully completed Stage 1 testing of a new molecule, metallofullerene, for the medical imaging industry. This... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is pleased to announce the formalization of a pivotal sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. This landmark agreement marks a significant milestone in Voyageur's journey, signaling its entry into the... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the completion of formulation and the engineering for production processing for the dry powdered barium contrast media product HDXBa TM . HDXBa TM is an oral contrast agent for suspension used as an oral drug for use in double-contrast radiographic... Read More

Calgary, Alberta - TheNewswire - August 1, 2023 - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) (USA: VYYRF) (the "Company" or "Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended May 31, 2023 on SEDAR+ (www.sedarplus.ca). Voyageur also announces the retirement from the Board of Directors of the Corporation (the " Board ") of Ron Sifton who has... Read More

Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur ") announces that on July 10, 2023, it issued 383,360 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company effective... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the release of the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX™, emphasising its... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM) (OTC:VYYRF) ("Voyageur" or the "Corporation ") announces the successful completion of environmental and geotechnical field work at its Frances Creek project site. This milestone represents a significant achievement for the Corporation and its 100% owned subsidiary, Voyageur Industrial Minerals Ltd., as it fulfills both the exploration notice of work for barite sampling from the... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( OTC :VYYRF) ("Voyageur" or the "Corporation"), announces it has entered into a groundbreaking development and license agreement with Rain Cage Carbon Inc. ("Rain Cage"). This strategic partnership aims to revolutionize the field by developing and manufacturing cutting-edge nanocarbon/fullerene-based contrast agents for medical imaging, utilizing Rain Cage’s innovative EDEN™ carbon... Read More

Calgary, AB - TheNewswire - April 28, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended February 28, 2023 on SEDAR. The Company also announces that on April 10, 2023, it issued 328,675 Deferred Share Units ("DSUs") to directors of the Company pursuant to its... Read More

Voyageur Pharmaceuticals CEO Brent Willis joins Proactive's Natalie Stoberman to share the latest results from its SmoothX comparative studies. Willis says results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75% of patients compared to the competing product. Before SmoothX goes to market, Willis adds a medical white paper is currently in preparation that will provide an in-depth... Read More

Calgary, Alberta – TheNewswire - April 4, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces that it has completed comparative studies of SmoothX® versus Readi-Cat ® 2% with taste test and Computed Tomography (CT) scans on patients. Results of the double-blind testing showed that SmoothX® was favoured on drinkability and taste by 75% of patients compared to the competing... Read More

Calgary, A B - TheNewswire - March 30, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2022 on SEDAR. The Company also announces that, due to a shortfall in spending on the Frances Creek project, because of closures to the site over the past... Read More

Calgary, Alberta – TheNewswire - February 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") continues to advance its sales and marketing programs and is preparing to launch its first product, SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market, in Canada. Voyageur announced today that Ethan Mohan has joined the Company’s sales team as Canadian Sales... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur ") announces that, further to its news release dated December 2, 2022, it has issued a total of 125,322 Common Shares at a deemed price of $0.09974 per Common Share for payment of outstanding debts of $12,500 owed to former directors of the Company and the outstanding debts have now been extinguished. The Common Shares issued by the Company have... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that, further to its news releases dated December 8 and 23, 2022 and January 12 and 20, 2023, the use of proceeds with respect to its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), were incorrectly totalled. The gross proceeds received by Voyageur from... Read More

Voyageur Pharmaceuticals Ltd . (TSXV:VM) ( OTC :VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 8 and 23, 2022 and January 12, 2023, it has completed the second and final closing of its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), issuing an aggregate of 14,570,764 Units for gross... Read More

News Release – TheNewswire - Calgary, Alberta – January 12, 2023: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 6 and 23, 2022, and due to strong investor demand for its non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit, it has increased the maximum size of the... Read More

News Release – Calgary, Alberta – TheNewswire - December 23, 2022 : Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news release dated December 6, 2022, it has completed the first closing of its non-brokered private placement of up to units of the Company (" Units ") for proceeds of up to CDN$650,000, with each Unit being sold at a price of... Read More

News Release – Calgary, Alberta – TheNewswire - December 8, 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has initiated its marketing campaign to introduce SmoothX ™ barium sulfate CT contrast media, to the CT Imaging market in Canada. SmoothX is a generic oral barium sulfate contrast media product, designed to assist in diagnosing disease using computed tomography... Read More

Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Units ("DSUs") to directors pursuant to its fixed 10% equity incentive compensation plan adopted by the Company following receipt of shareholder approval on June 28, 2021 (the "Plan"). Each DSU represents a right of the holder to... Read More

Calgary, Alberta – TheNewswire - November 28, 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces completion of the production test batch of its SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market in Canada. This development represents a significant transition for Voyageur from the development phase to the production phase, where the focus will... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") announces the completion of the design of its carbon neutral pharmaceutical plant and as such has accelerated the revenue generation timeline for the Frances Creek barium sulfate project, compared to stated timeline of the SGS Canada Inc preliminary economic assessment. ACH Engineering Inc has estimated the total capital cost to be CAD... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC :VYYRF) (the "Company" or "Voyageur") has signed a memorandum of understanding (MOU) with Rain Cage Carbon Inc. (RCC), to en ter into a development agreement for fullerene-based contrast agents. RCC, a carbon capture company located in Calgary, Alberta, has proven technology that removes CO 2 and other pollutants from hydrocarbon exhaust streams. The CO 2 is converted into... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC :VYYRF) (the "Company" or "Voyageur") has submitted a notice of work with the BC Ministry of Mines ( BCMM ), for the removal of 2,000 tonnes of barite in 2023. Upon approval from the BCMM, this sample will be used for testing on a new active pharmaceutical ingredient ( API ) pilot plant, that is tentatively scheduled to begin construction in 2023. Voyageur will excavate small,... Read More

Calgary, Alberta – TheNewswire - August 15 th , 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") has appointed Albert Deslauriers as interim CFO. Al held several senior financial positions with the Lafarge Group over a 34 year career including Vice President of Finance for Lafarge Canada. Al has a financial and general management background with major public corporations including... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated May 26 and 31, 2022, it has completed its non-brokered private placement of units of the Company (" Units ") at a price of $0.10 per Unit, issuing 11,570,000 Units for aggregate gross proceeds of $1,157,000 (the " Offering "). Each Unit is comprised of one (1) common share ("... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news release dated May 26, 2022, and due to strong investor demand for its recently announced non-brokered private placement of units of the Company (" Units ") at a price of $0.10 per Unit, it has increased the maximum size of the offering from 10,000,000 Units for gross proceeds of $1,000,000 to... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") is pleased to announce that it plans to complete a non-brokered private placement of up to 10,000,000 units (the " Units ") of Voyageur at a price of $0.10 per Unit for aggregate gross proceeds of up to $1,000,000 (the " Offering "). There is no minimum Offering. The Units will be comprised of one (1) common share (" Common Share ") and one... Read More

Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) is pleased to announce that it is progressing with its product development, regulatory pathway and material processing/manufacturing operations that could result in revenue generation in Canada this year and more importantly revenue generation in the United States early next year. Product Development As part of the product development process, Voyageur... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") has agreed to pay deposits for work on design of the Company's manufacturing facility and pay other existing debts in an amount of up to $100,000 through the issuance of common shares of the Company ("Common Shares") at a deemed price per share of $0.11 based on the closing price of the Common Shares at the close of trading on May 10, 2022 (the... Read More

Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the filing of its Preliminary Economic Assessment (“ PEA ”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “ Project ”), located in British Columbia, Canada. The PEA was initially disclosed in a news release dated January 11, 2022 and was prepared by SGS Geological Services (“ SGS... Read More

Calgary, Alberta – TheNewswire - February 16, 2022 - Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the completion of the NI 43-101 report, the Jubilee Mountain Property, authored by Craig Dunn, P.Geo, the effective date of February 4, 2022 (the " Report ") for the Jubilee Mountain copper polymetallic project (the " Jubilee Project "). In addition, Voyageur has... Read More

Voyageur Pharmaceuticals Ltd. (“ Voyageur ” or the “ Company ”) (TSXV:VM) is pleased to announce the results of its Preliminary Economic Assessment (“PEA”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “Project”), located in British Columbia, Canada. The PEA was prepared by SGS Geological... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC : VYYRF) (the "Company" or "Voyageur") has a preliminary economic assessment (PEA) on its Frances Creek project pending with SGS Canada, who have stated the first draft will be completed by mid December. There have been delays outside of management's control. Building out the mining operation and product manufacturing represents the second phase of Voyageur’s plan. Voyageur is... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce the signing of a non-binding Memorandum of Understanding (“MOU”) with Summit Nanotech Corporation (“SNT”). The MOU proposes an agreement between Voyageur and SNT to develop a more sustainable process for the production of iodine medical products, that are used as contrast agents. The process will be developed by... Read More

Voyageur Pharmaceuticals Ltd. (TSXV: VM) ( OTC :VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the completion of the formation of its Scientific Advisory Board (SAB), with the additions of two leading doctors in the radiology industry. The SAB is to support the firm’s... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC: VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the formation of its Scientific Advisory Board (SAB) to support the firm’s research, clinical and product development programs. The SAB is to provide our management team, BOD... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") has been working with SGS Canada Inc. on the Preliminary Economic Assessment (PEA) for its Frances Creek barium Quarry operation. A critical part of the PEA is the design of an upgrading system to process the Frances Creek barium concentrate to meet the requirements of the United States Pharmacopeia (USP). The upgrading process has been the... Read More

Calgary, Alberta – TheNewswire - August 12, 2021 – Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") announced that it has issued 200,000 options to directors pursuant to its incentive stock option plan (the “Options”). In addition, the Company announces it has issued 169,872 Deferred Share Units (“DSU’S”) to directors pursuant to its equity incentive compensation plan. The grants... Read More

Calgary, Alberta - TheNewswire - July 26 th , 2021 - Voyageur Pharmaceuticals Ltd . (TSXV : VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph Hesje are being appointed to the Voyageur Board as Director’s effective immediately. Voyageur is committed to create a strong independent board of directors with extensive experience in board management, business... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, and May 5 and 28, 2021, Voyageur has closed its financing and will not be proceeding with a third and final tranche of its non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). Pursuant to the Offering,... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, 2021 and May 5, 2021, it has closed the second tranche of a non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). The Offering is a combination of (i) Common Units issued at a price of $0.15 per Common... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick barium sulfate suspension that contains 105% w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract. Voyageur has built a full suite of barium radiographic contrast media products for global... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick barium sulfate suspension that contains 105% w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract. Voyageur has built a full suite of barium radiographic contrast media products for global... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension . MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension . MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has increased the previously announced non-brokered offering of units (the "Offering") from a maximum of $1,725,000 to $2,100,000. Further to the news release of the Company dated April 13 th , 2021, the Offering was a combination of Pricing as follows: A "Common Unit" priced at $0.15 where each Common Unit... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V : VM ) USA (OTC : VYYRF) (the “Company” or “Voyageur”), is pleased to announce that the D.C. Circuit Court of Appeals has upheld a prior ruling that conclude d radiographic contrast agent barium sulfate, qualifies as a device rather than a drug. This ruling has a significant impact on Voyageur’s planned product roll out into the United States (US). Management of Voyageur estimates that... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the “Company” or “Voyageur”), is pleased to announce a proposed non-brokered private placement financing of up to 11,500,000 units, for gross proceeds of up to $1,725,000 (the "Offering"). Under the Offering, the Company expects to raise up to $1,500,000, but has approved up to $1,725,000 to give the Company an option to increase the Offering by up to 15% to... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC:VYYRF ) (the "Company" or "Voyageur") announced that is has issued 2,625,000 options to directors, officers and consultants pursuant to its incentive stock option plan (the "Options"). On March 29, 2021, the Company's board of directors approved the grant of Options, to be effective on April 1, 2021 using the closing price on that day. The Options were issued with an exercise... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC :VYYRF ) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiX barium sulfate powder. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") announces that it has signed a cost plus manufacturing agreement with Alberta Veterinarian Laboratories Ltd. ("AVL"). This agreement allows Voyageur to begin the process of formulating and testing our new products with AVL and prepare for production and sales. AVL is committing mixing and fill lines for Voyageur's production.... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") announces that it has received $ 209,764.05 in cash proceeds from the exercise of previously issued warrants, finder's warrants and stock options. The proceeds will be allocated to continue to move the Company forward towards cash flow. Brent Willis, CEO of Voyageur, states “We are very appreciative to all the shareholders who continue... Read More

Voyageur Pharmaceuticals Ltd. ( TSX V : VM ) ( OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for its second product, HDX Ba . HDX Ba is a barium radiographic contrast powder for suspension that is specifically formulated for Fluoroscopy barium X-Ray procedures and can also be used for CT Scans. This approval authorizes the sale of HDX Ba for use in... Read More

Voyageur Pharmaceuticals Ltd. ( TSXV : VM ) USA (OTC : VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for SmoothX. SmoothX is a barium radiographic contrast suspension that is specifically formulated for computed tomography procedures (CT Scans). This approval authorizes the sale of SmoothX for use in radiology procedures in Canada. SmoothX is specifically... Read More